Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.
about
Hepatitis C: a review for primary care physiciansKASL clinical practice guidelines: management of hepatitis CAnalysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles.Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus QuasispeciesManaging Occupational Risks for Hepatitis C Transmission in the Health Care SettingFactors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic HepatitisRole of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopeniaPrevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.SComparison of hepatitis C viral loads in patients with or without human immunodeficiency virusThe unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, ChinaTreatment optimization for HIV/HCV co-infected patients.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection.Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV.The influence of host factors on the natural history of chronic hepatitis C viral infections.CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patientsHepatitis C infection in HIV-1 natural viral suppressors.Screening for hepatitis C virus in human immunodeficiency virus-infected individuals.Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infectionsThe Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10.New animal models of hepatitis B and C.Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy.Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression.Hepatitis C and human immunodeficiency virus infection.Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection.HCV viremia is associated with drug use in young HIV-1 and HCV coinfected pregnant and non-pregnant women.Predicting progression to cirrhosis in chronic hepatitis C virus infection.The history of the "natural history" of hepatitis C (1968-2009).Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine users in the United States.Hepatitis C and HIV-1 coinfection.Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.Cell culture models and animal models of viral hepatitis. Part II: hepatitis C.Coinfection with HIV and hepatitis C virus in injection drug users and minority populations.Growing importance of liver disease in HIV-infected persons.Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women.A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort Study
P2860
Q22306040-A1160524-8D17-4CCC-9186-02A7C390119BQ26752471-EC0941BB-A3A4-4E60-9F9E-6E682E9B1AF9Q27469551-BC3AC783-3B2B-4D72-8905-3634BF0B8147Q27469782-73B7C653-C7BA-47E7-A37A-C8C7648C3532Q27477626-EBA2C741-A86E-43C2-B5ED-85D1F26F098EQ27480999-9E60E7A2-92AA-445E-A075-2CF869E9BCEBQ27488342-DF642682-5F3D-4F18-9CA1-10E1A5920854Q27489610-4E1BFDAF-71F9-4DF7-B1FF-98CC55B32779Q28367786-63C9EB8A-B1B6-4BC1-BB15-EDF6BD880AEDQ28744366-AFBA9161-2FC4-4C74-8355-8B8094E802E0Q30235034-EA441520-0770-421A-BB47-B77378729B5EQ30355190-60BDBA28-94AE-478D-A11C-4CB998334A9AQ30429470-DA48DF1B-EDD9-45C7-8254-097B78FE3BBAQ33378514-01603352-09A6-45AD-9CB8-E7A05EB4728DQ33397264-D606C48B-F6DB-467A-B24B-06BA114D0B36Q33588960-FFBFB766-3AB3-41EA-9DF6-A6C8D70500FCQ33801341-20FB9345-9A8D-48BA-9779-2083D6AD1205Q33874737-0FD8EF3D-1F18-4105-B7CD-844A1C222C02Q33946635-E02F000C-0C35-49CE-BB44-E55CF8D4F2EEQ33952520-F81EA779-EA9C-4F9C-B282-84EB09966EFAQ33965308-00F637EC-5412-46F6-9E67-FE6AD8814970Q33999381-FC28F2ED-13D8-4107-B430-3088F1719245Q34218503-944E2AE5-7B0D-4765-9AB6-D557EF7A4B09Q34282823-3732EC4C-28C6-4A60-8C55-48DA86184C78Q34536150-3DF30B35-B698-4129-BA76-BE9E9DC49618Q34764615-7ED37A30-8440-4578-8B31-3C897A6F16ACQ34984125-A13CF5E3-09D2-4B68-95A3-8A63696A22D0Q35056266-6890A7E3-DD4D-4487-8846-68242DAE9F98Q35056682-67258088-966C-4E1A-BA4F-2718913F3750Q35161346-6EBDC36C-361D-49A1-A42A-2868B028CD5AQ35216592-3363D3FA-DAE5-4C86-99D5-4D07533A9053Q35575582-19E3F3B6-2FAC-4B04-BEE3-F0CE53246E7EQ35595027-903AA8A9-0257-495E-B12F-FE90DF022E08Q35595809-DFF9FD8B-9324-41A5-9850-3C2D1BF8BDC1Q35614631-728746BD-7FBD-4040-BB5B-C145751236ADQ36026752-E81113E5-98D9-45DC-9C3E-B352A6FD218BQ36304424-49E41A6B-8FE3-45E7-88D3-340BECAE0BEDQ36382240-D9193EEF-2D5A-4587-BD4D-FAA891C6E809Q36384812-3C383DB0-073A-4183-BE07-BD47801D3324Q36401521-8831192E-D3F7-40EB-BCFD-A3A684FD8DEA
P2860
Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Effect of human immunodeficien ...... on among injecting drug users.
@en
Effect of human immunodeficien ...... on among injecting drug users.
@nl
type
label
Effect of human immunodeficien ...... on among injecting drug users.
@en
Effect of human immunodeficien ...... on among injecting drug users.
@nl
prefLabel
Effect of human immunodeficien ...... on among injecting drug users.
@en
Effect of human immunodeficien ...... on among injecting drug users.
@nl
P2093
P356
P1476
Effect of human immunodeficien ...... on among injecting drug users.
@en
P2093
P304
P356
10.1093/INFDIS/174.4.690
P407
P577
1996-10-01T00:00:00Z